209 related articles for article (PubMed ID: 20484211)
1. Effects of antiplatelet and anticoagulant medications on the vasoocclusive and thrombotic complications of sickle cell disease: A review of the literature.
Charneski L; Congdon HB
Am J Health Syst Pharm; 2010 Jun; 67(11):895-900. PubMed ID: 20484211
[TBL] [Abstract][Full Text] [Related]
2. Low-molecular-weight heparins for managing vasoocclusive crises in people with sickle cell disease: a summary of a cochrane systematic review.
van Zuuren EJ; Fedorowicz Z
Hemoglobin; 2014; 38(3):221-3. PubMed ID: 24826795
[TBL] [Abstract][Full Text] [Related]
3. Large-vessel occlusion in sickle cell disease: pathogenesis, clinical consequences, and therapeutic implications.
Francis RB
Med Hypotheses; 1991 Jun; 35(2):88-95. PubMed ID: 1890982
[TBL] [Abstract][Full Text] [Related]
4. Hypercoagulability in sickle cell disease: a curious paradox.
Ataga KI; Orringer EP
Am J Med; 2003 Dec; 115(9):721-8. PubMed ID: 14693325
[TBL] [Abstract][Full Text] [Related]
5. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
[TBL] [Abstract][Full Text] [Related]
6. Sickle cell vasoocclusion: many issues and some answers.
Kaul DK; Nagel RL
Experientia; 1993 Jan; 49(1):5-15. PubMed ID: 8428611
[TBL] [Abstract][Full Text] [Related]
7. Hypercoagulability in sickle cell disease: new approaches to an old problem.
Ataga KI; Key NS
Hematology Am Soc Hematol Educ Program; 2007; ():91-6. PubMed ID: 18024615
[TBL] [Abstract][Full Text] [Related]
8. New concepts in assessing sickle cell disease severity.
Schnog JJ; Lard LR; Rojer RA; Van der Dijs FP; Muskiet FA; Duits AJ
Am J Hematol; 1998 May; 58(1):61-6. PubMed ID: 9590151
[TBL] [Abstract][Full Text] [Related]
9. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
[TBL] [Abstract][Full Text] [Related]
10. CT of Gastrointestinal Vasoocclusive Crisis Complicating Sickle Cell Disease.
Gardner CS; Jaffe TA
AJR Am J Roentgenol; 2015 May; 204(5):994-9. PubMed ID: 25905933
[TBL] [Abstract][Full Text] [Related]
11. Studies on the management and prevention of vasoocclusive crisis in sickle cell disease.
Ambrus JL; Ambrus CM; Bannerman R; Sills RH; Meky NN
J Med; 1984; 15(5-6):385-407. PubMed ID: 6100377
[TBL] [Abstract][Full Text] [Related]
12. A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons.
Brown DG; Wilkerson EC; Love WE
J Am Acad Dermatol; 2015 Mar; 72(3):524-34. PubMed ID: 25486915
[TBL] [Abstract][Full Text] [Related]
13. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
Konstantopoulos K; Mousa SA
Curr Opin Investig Drugs; 2001 Aug; 2(8):1086-92. PubMed ID: 11892918
[TBL] [Abstract][Full Text] [Related]
14. Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.
Hoppe CC; Styles L; Heath LE; Zhou C; Jakubowski JA; Winters KJ; Brown PB; Rees DC; Heeney MM
Pediatr Blood Cancer; 2016 Feb; 63(2):299-305. PubMed ID: 26402148
[TBL] [Abstract][Full Text] [Related]
15. Assessment of bleeding risk of interventional techniques: a best evidence synthesis of practice patterns and perioperative management of anticoagulant and antithrombotic therapy.
Manchikanti L; Falco FJ; Benyamin RM; Caraway DL; Kaye AD; Helm S; Wargo BW; Hansen H; Parr AT; Singh V; Swicegood JR; Smith HS; Schultz DM; Malla Y; Hirsch JA
Pain Physician; 2013 Apr; 16(2 Suppl):SE261-318. PubMed ID: 23615893
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper.
Culkin DJ; Exaire EJ; Green D; Soloway MS; Gross AJ; Desai MR; White JR; Lightner DJ
J Urol; 2014 Oct; 192(4):1026-34. PubMed ID: 24859439
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet drugs in the management of patients with thrombotic disorders.
Harker LA
Semin Thromb Hemost; 1986 Apr; 12(2):134-55. PubMed ID: 3016905
[No Abstract] [Full Text] [Related]
18. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.
Schömig A; Neumann FJ; Kastrati A; Schühlen H; Blasini R; Hadamitzky M; Walter H; Zitzmann-Roth EM; Richardt G; Alt E; Schmitt C; Ulm K
N Engl J Med; 1996 Apr; 334(17):1084-9. PubMed ID: 8598866
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Albers GW; Amarenco P; Easton JD; Sacco RL; Teal P
Chest; 2008 Jun; 133(6 Suppl):630S-669S. PubMed ID: 18574275
[TBL] [Abstract][Full Text] [Related]
20. Optimal antithrombotic treatment for percutaneous coronary intervention.
Kadakia RA; Ferguson JJ
Minerva Cardioangiol; 2005 Feb; 53(1):15-42. PubMed ID: 15788977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
